Navigation Links
Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Judge’s Decision to Fine Boehringer Ingelheim for Failing to Preserve Documents Relevant to Pradaxa Bleeding Claims
Date:12/10/2013

New York, NY (PRWEB) December 10, 2013

As hundreds of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/ ) continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP notes that the judge overseeing the proceeding has fined Boehringer Ingelheim nearly $1 million after determining that the company withheld or failed to preserve numerous documents sought by plaintiffs with cases pending in the litigation. In his December 9th ruling, U.S. District Judge David Herndon called the company’s conduct egregious, and ordered it to pay a sanction of over $931,000. He also wrote in his 51-page decision that Boehringer Ingelheim’s efforts to preserve the documents were “grossly inadequate” and that the company had “made misrepresentations” regarding its efforts. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

According to court documents, plaintiffs have asserted that Boehringer Ingelheim should have placed a litigation hold on certain documents pertaining to Pradaxa’s development, as well as the company’s marketing plan for the blood thinner. Plaintiffs in Pradaxa lawsuits also accused the company of failing to order employees to save phone messages pertaining to their work on the drug.

“We have heard from numerous plaintiffs seeking to file lawsuits over alleged Pradaxa bleeding. We are monitoring this litigation very closely as it moves towards its first bellwether trials later next year,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to individuals who suffered serious internal bleeding while using this medication.

Pradaxa Lawsuits
Court documents indicate that more than 1,700 lawsuits have been filed in the Southern District of Illinois on behalf of alleged victims of Pradaxa bleeding. All of the lawsuits accuse Boehringer Ingelheim of concealing knowledge about the drug’s risks when it was brought to market in October 2010. Plaintiffs also allege that the company failed to provide adequate warnings regarding the lack of an effective antidote for Pradaxa bleeding.

In October, the Institute for Safe Medicine Practices (ISMP) revealed that Pradaxa had been named in more adverse event reports than any other drug monitored by the U.S. Food & Drug Administration (FDA). In 2012, the FDA received 3,200 reports of Pradaxa side effect including 582 that had fatal outcomes. The same year, warfarin, a much older blood thinner, was the subject of just 861 reports, including 56 deaths. Among other things, the ISMP said that physicians should be provided with better information to manage the risks associated with Pradaxa, especially since there is currently no antidote for reversing the internal bleeding that is sometimes associated with its use.

Patients who allegedly suffered life-threatening episodes of internal bleeding while using Pradaxa may be entitled to compensation for their injuries. To learn more about potential Pradaxa bleeding side effects, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.pradaxalawsuithelp.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb11409727.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. As Pradaxa Lawsuits Move Forward, Bernstein Liebhard LLP Notes Manufacturer is Working on Possible Antidote for Internal Bleeding Caused by the Blood-Thinner
2. Pradaxa Lawsuit News: Wright & Schulte LLC Reports on Growing Pradaxa Bleeding Litigation, As Number of Filings Exceed 1,800
3. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on November Status Conference in Federal Pradaxa Bleeding Litigation
4. Pradaxa Bleeding Allegations Lawyer: Resource4thePeople Reports New Study May Produce Treatment to Reverse Anti-Clotting Medication Effects
5. Pradaxa Lawsuits Continue to Mount, With Filing of New Pradaxa Wrongful Death Claim in Pennsylvania by Wright & Schulte LLC
6. Pradaxa Lawsuits Progress, as Bernstein Liebhard LLP Notes Establishment of Bellwether Case Selection Protocol in Federal Pradaxa Bleeding Litigation
7. Pradaxa Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance of New Order in Federal Pradaxa Bleeding Litigation
8. New Data on Pradaxa Bleeding Side Effects Draws Comment from Pradaxa Lawsuit Lawyers at Wright & Schulte LLC
9. DrugRisk Alert: Pradaxa Leads Study of Complication Reports to FDA
10. DrugNews: Court Records Show Growth In Claims Alleging Pradaxa Bleeding Injury
11. Doyle Raizner Attorney Presenting Pradaxa MDL Update at AAJ Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... United Nations Foundation President ... the Mexico City Policy, also known as the Global Gag Rule, last enacted ... prohibits foreign non-governmental organizations from receiving any U.S. foreign assistance for family planning ...
(Date:1/24/2017)... ... 23, 2017 , ... Texas Home Health, an AccentCare, Inc. ... care service companies: Padre Home Health in Corpus Christi, Texas, and Royalty Personal ... regarded in their respective markets, these two agencies align with Texas Home Health’s ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... men who support them, Dr. Carol Francis, Psychologist in the South Bay ... pay, humane respectful governing for all people and by all people shines as ...
(Date:1/24/2017)... ... , ... The National Council of Alcoholism and Drug Dependence ( NCADD ), ... communities to designate the last full week of January as National Drug and Alcohol ... Myths.” As a community, we can advocate for effective treatment, but also especially ...
(Date:1/23/2017)... ... ... PKF O’Connor Davies , LLP, the nation’s 26th largest accounting and ... will participate in the 40th Annual "Empire State Building Run Up" on Feb. 1 ... a vertical distance equal to about a fifth of a mile, to reach the ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... SAN FRANCISCO , January 23, 2017 The global  ... USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated ... and psychotherapies has resulted in the declining demand for antidepressants in the recent ... ... Grand View Research Logo ...
(Date:1/23/2017)... Januar 2017  ResMed (NYSE: RMD ), ... Medical ( Winter Haven, Florida ) gaben ... die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ResMed ... leisten, um das in Florida ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
Breaking Medicine Technology: